treosulfan   Click here for help

GtoPdb Ligand ID: 8281

Synonyms: Trecondi®
Approved drug
treosulfan is an approved drug (UK (1992), EMA (2019))
Compound class: Synthetic organic
Comment: Treosulfan is a DNA alkylating agent.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: treosulfan

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 143.96
Molecular weight 278.01
XLogP -3.29
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(C(COS(=O)(=O)C)O)COS(=O)(=O)C
Isomeric SMILES OC(C(COS(=O)(=O)C)O)COS(=O)(=O)C
InChI InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3
InChI Key YCPOZVAOBBQLRI-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The EMA granted treosulfan orphan drug status to be used as a conditioning treatment prior to haematopoietic progenitor cell transplantation. The FDA has granted orphan drug status for the treatment of ovarian cancer. Four Phase 3 clinical trials assessing treosulfan as a conditioning treatment are ongoing, as are Phase 3 studies for ovarian cancer and Ewing's sarcoma. Full EMA approval was granted in 2019.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
As a DNA alkylating (cross-linking) agent, treosulfan treatment irreversibly interferes with DNA replication, RNA transcription and causes general disruption of nucleic acid function. This action causes cell death.